PTCT Q2 2024 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$187M-12.7% YoY

Gross Profit

$171M91.7% margin

Operating Income

-$40M-21.5% margin

Net Income

-$99M-53.1% margin

EPS (Diluted)

$-1.29

QoQ Revenue Growth

-11.1%

Cash Flow

Operating Cash Flow

-$71M

Free Cash Flow

-$64M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$2.9B

Stockholders' Equity

-$980M

Cash & Equivalents

$655M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$187M	$214M	-12.7%
Gross Profit	$171M	$201M	-14.9%
Operating Income	-$40M	-$210M	+80.8%
Net Income	-$99M	-$199M	+50.1%

Revenue Segments

Product

$133M71%

Royalty

$53M28%

Manufacturing

$800,0000%